ADAG Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

4 Analyst Rating

Wall Street analysts forecast ADAG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADAG is 8.00 USD with a low forecast of 7.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

7.00

Averages

8.00

High

9.00

Current: 0.000

Low

7.00

Averages

8.00

High

9.00

Guggenheim

initiated

2025-11-24

Reason

Guggenheim

Price Target

2025-11-24

initiated

Reason

As previously reported, Guggenheim initiated coverage of Adagene with a Buy rating and $9 price target. The company's lead product candidate muzastotug is currently in Phase 2 for patients with late-line microsatellite stable colorectal cancer without liver metastases, notes the analyst. The company has reported "compelling" Phase 1 data for muzastotug plus pembrolizumab that exceed current standard of care benchmarks in third-line and later CRC, according to the analyst, who calls this "an area of significant unmet need."

Guggenheim

initiated

2025-11-24

Reason

Guggenheim

Price Target

2025-11-24

initiated

Reason

Guggenheim initiated coverage of Adagene with a Buy rating and $9 price target.

LifeSci Capital

Outperform

initiated

2025-11-14

Reason

LifeSci Capital

Price Target

2025-11-14

initiated

Outperform

Reason

LifeSci Capital initiated coverage of Adagene with an Outperform rating and $8 price target.

Lucid Capital

NULL

Buy

initiated

2025-09-18

Reason

Lucid Capital

Price Target

2025-09-18

initiated

NULL

Buy

Reason

Lucid Capital initiated coverage of Adagene with a Buy rating and $9 price target. Adagene is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based cancer immunotherapies, the analyst tells investors in a research note. The firm estimates peak sales of $1.2B by 2039 for the company's lead asset muzastotug in metastatic colorectal cancer patients with no liver metastases. Lucid sees \"significant\" upside in the shares if the data continue to support a potential best-in-indication profile.

H.C. Wainwright

Arthur He

Buy

downgrade

$8 -> $7

2025-08-15

Reason

H.C. Wainwright

Arthur He

Price Target

$8 -> $7

2025-08-15

downgrade

Buy

Reason

H.C. Wainwright analyst Arthur He lowered the firm's price target on Adagene to $7 from $8 and keeps a Buy rating on the shares. The firm updated the company's model to reflect delayed launches of ADG126.

Leerink

Outperform

initiated

2025-08-06

Reason

Leerink

Price Target

2025-08-06

initiated

Outperform

Reason

Leerink initiated coverage of Adagene with an Outperform rating and $7 price target. The firm's positive view of the company and stock is grounded in enthusiasm for the company's lead program, muzastotug, which is a conditionally masked CTLA-4 antagonist. As emphasis on biotech in China increases, Adagene is well positioned to benefit from increased investment in the region, Leerink adds.

Valuation Metrics

The current forward P/E ratio for Adagene Inc (ADAG.O) is -2.02, compared to its 5-year average forward P/E of -3.27. For a more detailed relative valuation and DCF analysis to assess Adagene Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.27

Current PE

-2.02

Overvalued PE

-0.26

Undervalued PE

-6.28

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.40

Current EV/EBITDA

-0.77

Overvalued EV/EBITDA

1.80

Undervalued EV/EBITDA

-4.59

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

15.96

Current PS

0.00

Overvalued PS

42.37

Undervalued PS

-10.44

Financials

Annual

Quarterly

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ADAG News & Events

Events Timeline

No data

News

9.0

2025-12-17NASDAQ.COM

FDA Approves Fast Track Status for ADAG's Colorectal Cancer Treatment

9.0

2025-12-16Globenewswire

Adagene Receives FDA Fast Track Designation for muzastotug in MSS Colorectal Cancer

9.0

2025-12-16Newsfilter

Adagene Receives FDA Fast Track Designation for muzastotug in MSS Colorectal Cancer

People Also Watch

Frequently Asked Questions

What is Adagene Inc (ADAG) stock price today?

The current price of ADAG is 1.53 USD — it has decreased -7.27 % in the last trading day.

What is Adagene Inc (ADAG)'s business?

Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.

What is the price predicton of ADAG Stock?

What is Adagene Inc (ADAG)'s revenue for the last quarter?

Adagene Inc revenue for the last quarter amounts to NaN USD, decreased % YoY.

What is Adagene Inc (ADAG)'s earnings per share (EPS) for the last quarter?

Adagene Inc. EPS for the last quarter amounts to USD, decreased % YoY.

What changes have occurred in the market's expectations for Adagene Inc (ADAG)'s fundamentals?

The market is revising No Change the revenue expectations for Adagene Inc. (ADAG) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -19.90%.

How many employees does Adagene Inc (ADAG). have?

Adagene Inc (ADAG) has 138 emplpoyees as of January 11 2026.

What is Adagene Inc (ADAG) market cap?

Today ADAG has the market capitalization of 72.11M USD.